ストックスクリーナーアプリを入手
10.02
0.69%
-0.07
前日終値:
$10.09
開ける：
$10.0418
24時間の取引高:
18,270
Relative Volume:
0.03
時価総額：
$7.06M
収益：
-
当期純損益:
$-9.60M
株価収益率:
-3.1709
EPS:
-3.16
ネットキャッシュフロー:
$-8.96M
1週間 パフォーマンス:
+20.00%
1か月 パフォーマンス:
-37.65%
6か月 パフォーマンス:
+40.34%
1年 パフォーマンス:
+24.64%
1日の値動き範囲:
$9.90
$10.40
1週間の範囲:
$8.50
$10.40
52週間の値動き範囲:
$4.9176
$28.60
Artelo Biosciences Inc Stock (ARTL) Company Profile
名前
Artelo Biosciences Inc
セクター
電話
858-925-7049
住所
505 LOMAS SANTA FE, SUITE 160, SOLANA BEACH, CA
ARTL を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ARTL
Artelo Biosciences Inc
|
10.02 | 7.07M | 0 | -9.60M | -8.96M | -3.16 |
|
VRTX
Vertex Pharmaceuticals Inc
|
392.79 | 100.07B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
580.41 | 59.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
448.91 | 58.03B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
653.83 | 39.93B | 3.06B | 1.28B | -614.78M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
321.36 | 36.82B | 3.81B | -644.79M | -669.77M | -6.24 |
Artelo Biosciences Inc Stock (ARTL) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-07-08 | アップグレード | D. Boral Capital | Hold → Buy |
| 2021-02-12 | 開始されました | Ladenburg Thalmann | Buy |
Artelo Biosciences Inc (ARTL) 最新ニュース
Artelo Biosciences Q2 2025 Earnings: Negative Earnings, Mixed Market Reactions - AInvest
Artelo Biosciences Reports Increased Losses Amid Strategic Investments - TipRanks
Artelo Biosciences Q2 Earnings: $5.61 EPS, FABP5 Inhibitor Pipeline Advances - AInvest
Artelo Biosciences Provides Business Update and Reports Second Q - GuruFocus
ARTELO BIOSCIENCES, INC. SEC 10-Q Report - TradingView
Artelo Biosciences Nears Major Clinical Readouts as Cash Position Strengthens to $13M - Stock Titan
Is It Too Early to Call Recovery in Artelo Biosciences Inc.July 2025 Fed Impact & AI Powered Market Entry Ideas - 선데이타임즈
Artelo Biosciences Receives Patent Protection Extension in Europe - mg Magazine
How to interpret RSI for Artelo Biosciences Inc. stockFree Portfolio Diversification Stock Ideas - Newser
Chart based exit strategy for Artelo Biosciences Inc.Free Optimized Watchlist With Daily Adjustments - Newser
Will Artelo Biosciences Inc. rebound enough to break evenBuy and Hold Return Summary with Charts - Newser
Artelo Biosciences Secures European Patent for ART27.13 Commercial Formulation, Extending Protection Through 2041 - AInvest
Risk vs reward if holding onto Artelo Biosciences Inc.ROI Focused Setup With Drawdown Analysis - Newser
Artelo Biosciences Surges 19.4% on Landmark Patent Approval for Cancer Anorexia Drug ART27.13 - AInvest
Artelo Biosciences secures European patent protection for cancer drug By Investing.com - Investing.com Nigeria
Artelo Biosciences secures European patent protection for cancer drug - Investing.com
Artelo Biosciences Receives Notice of Allowance from - GlobeNewswire
European Patent Win Secures 20-Year Protection for Revolutionary Cancer Anorexia Treatment in Phase 2 Trials - Stock Titan
Technical signs of recovery in Artelo Biosciences Inc.Free Value Investing Picks With Stability - Newser
What institutional flow reveals about Artelo Biosciences Inc.Breakout Watcher with Entry and Exit Alerts - Newser
Using Bollinger Bands to evaluate Artelo Biosciences Inc.Intraday Signal Forecast for Fast Traders - Newser
Multi factor analysis applied to Artelo Biosciences Inc.Swing Trade Watchlist with Entry Zones - Newser
Does Artelo Biosciences Inc. qualify in momentum factor screeningTrading Volume Anomaly Summary and Insight - Newser
Solana News Today: Solana Climbs 4.05% as Artelo Biosciences Invests $9.475M in Treasury - AInvest
Combining price and volume data for Artelo Biosciences Inc.Forecast Model for Intraday Buy Signals - Newser
Artelo Biosciences Partners with ABK Labs for Strategic Growth - The Globe and Mail
Artelo Biosciences (ARTL) down more than 70% since Jul 11 - AInvest
Artelo Biosciences Inc. Moves Into Bullish Territory Based on MACDEntry Alert With Low Drawdown Strategy Noted - beatles.ru
Will a bounce in Artelo Biosciences Inc. offer an exitTrade Ideas Based on Fundamental Metrics - Newser
Artelo Biosciences Closes $9.475 Million Private Placement to Adopt Solana as Core Reserve Asset - AInvest
Artelo Biosciences (ARTL) down more than 50% since Jul 10 - AInvest
Artelo Biosciences Sees 15min Chart Trigger KDJ Golden Cross, Bullish Marubozu - AInvest
Analyst Maintains Buy Rating on ARTL with Target Price of $18 | - GuruFocus
Artelo Biosciences: Boral Capital maintains Buy, PT raised to $18 from $15. - AInvest
Biocardia Stock Plunges 12.76% Amid Market Volatility - AInvest
Artelo Biosciences announces private placement to initiate Solana treasury - TipRanks
Artelo Biosciences stock soars after announcing $9.5M private placement for Solana-based treasury - Investing.com Canada
Artelo Biosciences (ARTL): D. Boral Capital Adjusts Price Target, Maintains Buy Rating | ARTL Stock News - GuruFocus
Artelo Biosciences stock rating reaffirmed at Buy by D. Boral Capital - Investing.com Nigeria
Solana News Today: Artelo Biosciences Allocates $9.475M to Build Solana Digital Asset Reserve Strategy - AInvest
Artelo Biosciences shares surge after unveiling $9.5M private placement tied to Solana-based treasury plan - MSN
Solana News Today: Artelo Biosciences Adopts Solana as Treasury Asset After $9.475M Raise - AInvest
Artelo Biosciences Soars 13.73% on Clinical Trial Success, Blockchain Strategy - AInvest
Artelo Biosciences Initiates SOL Treasury Strategy with PIPE Financing, Partnering with CUBE and Bartosz Lipiński - Quiver Quantitative
Artelo Biosciences Announces $9.475 Million At-the-Market Private Placement to Initiate Solana Treasury Strategy, Becoming First Publicly-Traded Pharmaceutical Company to Adopt SOL as a Core Reserve Asset - The Manila Times
Artelo Biosciences raises $9.5M, adopts Solana as treasury asset By Investing.com - Investing.com Nigeria
Artelo Biosciences raises $9.5M, adopts Solana as treasury asset - Investing.com India
Artelo Biosciences raises $9.5M in PIPE, expands SOL treasury management strategy. - AInvest
Artelo Biosciences Announces $9.475 Million At-the-Market - GlobeNewswire
Artelo Biosciences Launches Solana Treasury Strategy, Becoming First Publicly-Traded Pharmaceutical Company to Adopt SOL - AInvest
Pharmaceutical Pioneer Artelo Makes History: Raises $9.5M to Build First-Ever Solana Treasury Strategy - Stock Titan
Artelo Biosciences Inc (ARTL) 財務データ
収益
当期純利益
現金流量
EPS
0.41%
0.88%
大文字化:
|
ボリューム (24 時間):